MedTrace Logo

Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen

NCT00408668 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2006-12-07

No results posted yet for this study

Summary

The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.

Conditions

Interventions

BIOLOGICAL

PEV3A

BIOLOGICAL

FP9 ME-TRAP

BIOLOGICAL

MVA ME-TRAP

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Pevion Biotech Ltd

    collaborator INDUSTRY

  • Swiss Tropical & Public Health Institute

    collaborator OTHER

  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED

  • University of Oxford

    lead OTHER

Principal Investigators

  • Adrian VS Hill, MA, BM BCh, DPhil, DM · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-08-31
Completion
2006-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408668 on ClinicalTrials.gov